SCAGNOLI, SIMONE
 Distribuzione geografica
Continente #
EU - Europa 1.054
NA - Nord America 863
AS - Asia 416
SA - Sud America 51
AF - Africa 13
Continente sconosciuto - Info sul continente non disponibili 1
Totale 2.398
Nazione #
US - Stati Uniti d'America 848
IT - Italia 670
SG - Singapore 249
SE - Svezia 116
DE - Germania 58
CN - Cina 51
BR - Brasile 49
IN - India 45
RU - Federazione Russa 35
FI - Finlandia 32
ID - Indonesia 23
NL - Olanda 22
GB - Regno Unito 20
BG - Bulgaria 16
AT - Austria 15
CA - Canada 15
IE - Irlanda 15
HK - Hong Kong 13
FR - Francia 10
IR - Iran 8
CH - Svizzera 7
RO - Romania 7
UA - Ucraina 7
EE - Estonia 5
ZA - Sudafrica 5
CZ - Repubblica Ceca 3
ES - Italia 3
IQ - Iraq 3
MA - Marocco 3
MK - Macedonia 3
PL - Polonia 3
UZ - Uzbekistan 3
AE - Emirati Arabi Uniti 2
AZ - Azerbaigian 2
BD - Bangladesh 2
IL - Israele 2
JP - Giappone 2
KR - Corea 2
KZ - Kazakistan 2
LT - Lituania 2
TG - Togo 2
TR - Turchia 2
AM - Armenia 1
AR - Argentina 1
BY - Bielorussia 1
DZ - Algeria 1
EC - Ecuador 1
EG - Egitto 1
EU - Europa 1
GR - Grecia 1
HR - Croazia 1
JO - Giordania 1
KE - Kenya 1
LA - Repubblica Popolare Democratica del Laos 1
MY - Malesia 1
RS - Serbia 1
SK - Slovacchia (Repubblica Slovacca) 1
TW - Taiwan 1
Totale 2.398
Città #
Rome 269
Singapore 142
Fairfield 112
Chandler 99
Ashburn 50
Santa Clara 50
Milan 44
Houston 40
Seattle 40
Woodbridge 35
Wilmington 31
Cambridge 27
Helsinki 27
Cosenza 26
San Paolo di Civitate 26
Dearborn 25
Jakarta 23
New York 23
Princeton 22
Sofia 16
Dublin 15
Florence 15
Lawrence 15
Nuremberg 15
San Diego 15
Millbury 13
Bremen 12
Hong Kong 11
Los Angeles 11
Ann Arbor 10
Naples 9
Turin 9
Vienna 9
Falkenstein 8
Moscow 8
Toronto 8
Caserta 7
Hyderabad 7
Beijing 6
Boardman 6
Boston 6
London 6
Plano 6
Ercolano 5
Fremont 5
L’Aquila 5
Redwood City 5
Salt Lake City 5
Stockholm 5
Tallinn 5
Andover 4
Bologna 4
Bühl 4
Dallas 4
Edinburgh 4
Frankfurt am Main 4
Guangzhou 4
Lappeenranta 4
Minusio 4
Ottawa 4
Baghdad 3
Council Bluffs 3
Deiva Marina 3
Germiston 3
Latina 3
Livorno 3
Lucca 3
Modena 3
Norwalk 3
Perugia 3
Reggio Calabria 3
Sacramento 3
Shanghai 3
Tashkent 3
Trento 3
Venice 3
Yubileyny 3
Amsterdam 2
Anzio 2
Baku 2
Bronte 2
Campo Grande 2
Casatenovo 2
Casavatore 2
Dubai 2
Elk Grove Village 2
Falls Church 2
Genoa 2
Groningen 2
Indore 2
Kunming 2
Leawood 2
Lençóis Paulista 2
Lomé 2
Lumezzane 2
Massa 2
Nanjing 2
Newark 2
Novara 2
Pescara 2
Totale 1.526
Nome #
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: a real-world experience 127
Immune effects of CDK4/6 inhibitors in patients with HR+/HER2− metastatic breast cancer: relief from immunosuppression is associated with clinical response 122
Anti–PD-1 and Anti–PD-L1 in head and neck cancer: a network meta-analysis 115
Burned-out testicular cancer: really a different history? 113
P-158Radioembolization (SIRT) as a Consolidation Treatment in Colorectal Liver Metastases after First Line Chemotherapy: Efficacy Safety 102
Prolactin as a potential negative predictive factor in metastatic non-small cell lung cancers (NSCLC) patients in treatment with Nivolumab (NIVO) 102
Cdk4/6 inhibitor treatments in patients with hormone receptor positive, her2 negative advanced breast cancer. Potential molecular mechanisms, clinical implications and future perspectives 102
The agnostic role of site of metastasis in predicting outcomes in cancer patients treated with immunotherapy 99
The role of opioids in cancer response to immunotherapy 96
Adjuvant chemotherapy in resected colon cancer: when, how and how long? 90
Exploratory pilot study of circulating biomarkers in metastatic renal cell carcinoma 87
Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach 85
Tissue immune profile: a tool to predict response to neoadjuvant therapy in triple negative breast cancer 85
The role of soluble LAG3 and soluble immune checkpoints profile in advanced head and neck cancer: a pilot study 84
E50Safety and toxicity in elderly patients in treatment for metastatic colon cancer 83
5-Fluorouracil degradation rate as a predictive biomarker of toxicity in breast cancer patients treated with capecitabine 77
Circulating CD137+ T cell levels are correlated with response to pembrolizumab treatment in advanced head and neck cancer patients 72
Tryptophan Catabolism as Immune Mechanism of Primary Resistance to Anti-PD-1 71
Late immune-related adverse events in long-term responders to PD-1/PD-L1 checkpoint inhibitors: A multicentre study 70
Standard of care and promising new agents for the treatment of mesenchymal triple-negative breast cancer 65
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting 59
Real-World Outcomes of Trastuzumab Deruxtecan in Patients With HER2+ Metastatic Breast Cancer: The DE-REAL Study 56
Clinical implications of the Drug-Drug Interaction in Cancer Patients treated with innovative oncological treatments 55
The Role of the CDK4/6 Inhibitor Ribociclib in Locally Advanced and Oligometastatic Hormone Receptor Positive, Her2 Negative, Advanced Breast Cancer: Case Series and Review of the Literature 53
The role of immune profile in predicting outcomes in cancer patients treated with immunotherapy 51
The impact of drug–drug Interactions on the toxicity profile of combined treatment with BRAF and MEK Inhibitors in patients with BRAF-mutated metastatic melanoma 51
Comparative effects of Folfirinox and Gemcitabine/nab-paclitaxel as first and second line chemotherapy for metastatic pancreatic cancer: single choice or sequence 46
Clinical impact of drug-drug interactions on abemaciclib in the real-world experience of AB-ITALY study 38
Impact of baseline and on-treatment glycemia on everolimus-exemestane efficacy in patients with hormone receptor-positive advanced breast cancer (EVERMET) 37
Network approach in liquidomics landscape 34
Assessing risks and knowledge gaps on the impact of systemic therapies in early breast cancer on female fertility: A systematic review of the literature 30
Circulating CD137+ T cell levels are correlated with response to Pembrolizumab treatment in advanced head and neck cancer patients 28
Pathologic response and survival after neoadjuvant chemotherapy with or without pertuzumab in patients with HER2-positive breast cancer: the Neopearl nationwide collaborative study 28
Ramucirumab as Second-Line Therapy in Metastatic Gastric Cancer. Real-World Data from the RAMoss Study 27
Second medical opinion in oncological setting 26
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study 25
Soluble Immune Checkpoints, Gut Metabolites and Performance Status as Parameters of Response to Nivolumab Treatment in NSCLC Patients 24
Safety of extended interval dosing immune checkpoint inhibitors. A multicenter cohort study 23
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from CaRe, a multicentric, observational study 20
Immune responses and clinical outcomes following the third dose of SARS-CoV-2 mRNA-BNT162b2 vaccine in advanced breast cancer patients receiving targeted therapies: a prospective study 15
null 3
Totale 2.576
Categoria #
all - tutte 10.036
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 10.036


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2019/202052 0 0 0 0 0 0 0 0 0 19 16 17
2020/2021186 12 12 18 22 8 14 5 6 28 31 16 14
2021/2022324 19 10 22 16 37 29 9 26 21 10 86 39
2022/2023515 74 79 41 51 56 49 7 35 31 28 42 22
2023/2024414 13 38 38 31 50 53 38 43 7 39 36 28
2024/2025897 31 30 58 135 103 84 85 94 167 110 0 0
Totale 2.576